HTGF News

Stay up to date

Our press pages provide up-to-date information on important developments at the High-Tech Gründerfonds and in the HTGF family. This also includes news from our portfolio companies.

We are the media’s go-to contact for all matters relating to start-ups, venture capital and, of course, our portfolio companies. Please get in touch with us.

Tobias Jacob – Senior Marketing & Communications Manager
Press
13. February 2025

InfectoPharm invests in AudioCure to advance innovative hearing loss therapy

Drug candidate AC102 in the clinical phase Heppenheim/Berlin, 13 February 2025 – There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence
 
Press
6. February 2025

Modular. Data-driven. Connected. Avelios Medical secures €30 million from Sequoia Capital for its next-generation hospital information system

The funding round is one of the largest Series A rounds in digital health in recent months. Avelios Medical offers the HIS of the future: designed around hospital workflows, powered by modular microservices, and based on structured data to enable AI-driven care. Leading hospitals are successfully using Avelios Medical’s software as the modern alternative in the HIS market. Munich, February 6, 2025 – Avelios Medical, provider of a modern hospital information system (HIS), h
 
Press
4. February 2025

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion Experienced team with a background in biotechnology and company building led by co-CEO’s Dr. Michael Krohn and Lukas Linnig Dr. Paul Scholz, the principal inventor of G-dase E technology, joins as Head of Research and Development Akribion Therapeutics (“Akribion”), the earl
 
Press
30. January 2025

Variolytics Secures Growth Financing Round with Nordic Alpha Partners

Stuttgart, January 30th, 2025 – Variolytics is delighted to announce the successful closure of its growth financing round, a significant milestone in the company’s mission to decarbonize the wastewater sector. The financing round, led by Nordic Alpha Partners (NAP), also includes investments from the European Innovation Council (EIC), High-Tech Gründerfonds (HTGF), and Fraunhofer Technology Transfer Fonds (FTTF). Founded in 2020 as a spin-off from the Fraunhofer Institute, Variolytic